ClinicalTrials.gg
CompletedNCT01004003Updated Oct 26, 2017Results posted

Phase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma

A Phase 2 interventional study of Sorafenib and BIBF 1120 in Carcinoma, Hepatocellular, sponsored by Boehringer Ingelheim. Completed at 28 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-10-26.

Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
125
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 149 studies in Carcinoma, Hepatocellular with a site in Germany — 23 open to participants now, 38 under way, 9 of them phase 3. Carcinoma, Hepatocellular · Germany.

Enrollment
64th of 124
125 · median 128
Started
2009
with 5 others
Phase 2
43 of 149
5 open now
Registered
26th of 149
by date

Among the 149 studies in Carcinoma, Hepatocellular with a site in Germany, this one is the 64th largest by enrollment of the 124 interventional ones that give a count, is one of 6 that started in 2009, is one of 43 in phase 2, and was the 26th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

23 of the 149 studies in Carcinoma, Hepatocellular with a site in Germany are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 149 studies in Carcinoma, Hepatocellular with a site in Germany, or all of them as a file.
02

Study summary

The study aim is to determine maximally tolerated dose (MTD) of BIBF 1120 in HCC (hepatocellular cancer) and compare efficacy of BIBF 1120 to Sorafenib in HCC patients

03

Conditions studied

  • Carcinoma, Hepatocellular
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed diagnosis of hepatocellular carcinoma (HCC) not amenable to curative surgery or loco-regional therapy (RFA, percutaneous ethanol injection (PEI), TACE)
  • Age 18 years or older
  • performance score of 2 or less
  • score A (score 5-6)
  • At least one according to 1.0 (this criterion is limited to phase II only)
  • In case a measurable lesion was previously treated by loco-regional therapy (RFA, PEI, TACE or RT) , this lesion must have to be documented as progression according to RECIST 1.0 by CT or MRI (this criterion is limited to phase II only).
  • Time interval from last local therapy (e.g. radiofrequency ablation, percutaneous ethanol injection, radiotherapy, transarterial chemoembolization) more than 4 weeks prior to start of study treatment
  • Written consistent with International Conference on Harmonisation/ Good Clinical Practice (ICH-GCP) and local legislation

Exclusion criteria

Exclusion criteria:

  • Prior systemic therapy for HCC
  • Fibrolamellar hepatocellular carcinoma (HCC)
  • greater than 1.5 times
  • or ALT greater than 2 times ULN
  • Uncontrolled or ascites to adequate medical therapy
  • Hepatic encephalopathy more than grade 1 according to criteria
  • international normalized ratio greater than 2.3, or prothrombin time more than 6 seconds prolonged than control
  • less than 1000 /µL
  • count less than 60000 /µL
  • less than 9 g/dL
  • Serum creatinine greater than 1.5 times Upper Limit of Normal (ULN)
  • Proteinuria of (CTCAE) grade 2 or greater
  • Variceal bleeding within last 6 months prior to start of study treatment
  • History of major thrombotic (except portal vein thrombosis) or major bleeding event in the past 6 months
  • Known inherited predisposition to bleeding or thrombosis
  • Significant cardiovascular diseases (i.e. hypertension not controlled by medical therapy, blood pressure > 150/90 mmHg), unstable angina, history of myocardial infarction within the past 6 months, congestive heart failure > class II according to (NYHA), serious cardiac arrhythmia, pericardial effusion)
  • Therapeutic anticoagulation (except low dose heparin and/or heparin flush as needed for maintenance of an indwelling intravenous device) or antiplatelet therapy (except for chronic low-dose therapy with acetylsalicylic acid =\< 325mg per day)
  • Major surgery within 4 weeks prior to start of study treatment
  • Treatment with other drugs or participation in another clinical trial within the past four weeks before start of therapy or concomitantly with this trial (except for present trial drug)
  • Known serious illness or concomitant non-oncological disease such as neurologic, psychiatric, infectious disease or active ulcers (gastro-intestinal tract, skin) or laboratory abnormality that may increase the risk associated with study participation or study drug administration and in the judgment of the investigator would make the patient inappropriate for entry into the study
  • Patients who are sexually active and unwilling to use a medically acceptable method of (e.g. such as implants, injectables, combined oral contraceptives, some intrauterine devices or vasectomized partner for participating females, condoms for participating males) during the trial and for at least twelve months after end of active therapy
  • Current alcohol abuse or drug abuse that would limit pt ability to comply with protocol
  • Symptomatic central nervous system (CNS)
  • less than 12 weeks
  • Patient unable to take oral medication
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
125 participants (actual)

Study arms

  • Experimental
    BIBF 1120

    Phase I dose escalation and phase II using dose determined in phase I ( 200 mg BID)

    Drug: BIBF 1120

  • Active comparator
    Sorafenib

    Drug: Sorafenib

Interventions

  • Dose escalated in phase I until MTD or adjusted by investigator, dose in phase II part based on phase I data

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose in Phase I

    The MTD was defined as the highest dose studied for which the incidence of dose limiting toxicities (DLTs) was 0/3 or less than 2/6 patients during the first treatment course.

    Time frame: 4 weeks

  2. Time to Progression (TTP) in Phase II

    TTP according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.0 criteria based on central independent review. TTP RECIST 1.0 was defined as the time from randomisation to disease progression according to RECIST 1.0.

    Time frame: From randomization until data cut-off (15 July 2014); Up to 1031 days

Secondary outcomes

  1. Incidence of Dose Limiting Toxicity in Phase I

    Number of patients with dose limiting toxicity are presented

    Time frame: 4 weeks

  2. Objective Tumour Response by RECIST

    Objective RECIST 1.0 tumour response was defined as Complete Response (CR) or Partial Response (PR) and was derived from the patient's best objective RECIST 1.0 response based on central independent review. 95% Confidence Interval presented below are computed by Clopper and Pearson method.

    Time frame: From randomization until data cut-off (15 July 2014); Up to 1031 days

  3. Progression Free Survival (PFS)

    PFS by RECIST 1.0 was defined as the duration from date of randomisation to date of progression or death, whichever occurred earlier, based on central independent review.

    Time frame: From randomization until data cut-off (15 July 2014); Up to 1031 days

  4. Overall Survival

    Overall survival was defined as the duration from date of randomisation to the date of death.

    Time frame: From randomization until data cut-off (15 July 2014); Up to 1031 days

07

Results

Posted Aug 7, 2015

Participant flow

Participant flow — Overall Study
MilestonePhase 1 Group 1, 100mg Nintedanib BidPhase I Group 1, 150mg Nintedanib BidPhase I Group 1, 200mg Nintedanib BidPhase I Group 2, 50mg Nintedanib BidPhase I Group 2, 100mg Nintedanib BidPhase I Group 2, 150mg Nintedanib BidPhase I Group 2, 200mg Nintedanib BidPhase II, 200 mg Nintedanib BidPhase II, 400 mg Sorafenib Bid
Started63434486231
Completed000000021
Not completed63434486030
Withdrew: Progressive disease21102113922
Withdrew: Adverse event4233227216
Withdrew: Refused to continue taking trial med.000000002
Withdrew: Other000001000

Outcome measures

PrimaryMaximum Tolerated Dose in Phase I

The MTD was defined as the highest dose studied for which the incidence of dose limiting toxicities (DLTs) was 0/3 or less than 2/6 patients during the first treatment course.

Time frame:
4 weeks
Reported as:
Number · mg bid
Maximum Tolerated Dose in Phase I
mg bidGroup 1Group 2
Maximum Tolerated Dose in Phase I200200
PrimaryTime to Progression (TTP) in Phase II

TTP according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.0 criteria based on central independent review. TTP RECIST 1.0 was defined as the time from randomisation to disease progression according to RECIST 1.0.

Time frame:
From randomization until data cut-off (15 July 2014); Up to 1031 days
Reported as:
Median · months
Time to Progression (TTP) in Phase II
monthsPhase II, 200 mg Nintedanib BidPhase II, 400 mg Sorafenib Bid
Time to Progression (TTP) in Phase II5.45 (2.69 to 9.20)4.63 (2.79 to 20.40)
Statistical analysis
  • Phase II, 200 mg Nintedanib Bid vs Phase II, 400 mg Sorafenib Bid · Hazard ratio (hr): 1.437 · 95% CI 0.805 to 2.565Hazard ratio (HR) from Cox proportional hazards model stratified by macroscopic vacular invasion, extrahepatic spread, or both present vs both absent. HR below 1 favors Nintedanib.
SecondaryIncidence of Dose Limiting Toxicity in Phase I

Number of patients with dose limiting toxicity are presented

Time frame:
4 weeks
Reported as:
Number · participants
Incidence of Dose Limiting Toxicity in Phase I
participantsPhase I Group I, 100 mg Nintedanib BidPhase I Group 1, 150 mg Nintedanib BidPhase I Group 1, 200 mg Nintedanib BidPhase I Group 2, 50 mg Nintedanib BidPhase I Group 2, 100 mg Nintedanib BidPhase I Group 2, 150 mg Nintedanib BidPhase I Group 2, 200 mg Nintedanib Bid
Incidence of Dose Limiting Toxicity in Phase I0000000
SecondaryObjective Tumour Response by RECIST

Objective RECIST 1.0 tumour response was defined as Complete Response (CR) or Partial Response (PR) and was derived from the patient's best objective RECIST 1.0 response based on central independent review. 95% Confidence Interval presented below are computed by Clopper and Pearson method.

Time frame:
From randomization until data cut-off (15 July 2014); Up to 1031 days
Reported as:
Number · percentage of participants
Objective Tumour Response by RECIST
percentage of participantsPhase II, 200 mg Nintedanib BidPhase II, 400 mg Sorafenib Bid
Objective Tumour Response by RECIST1.6 (0.0 to 8.7)6.5 (0.8 to 21.4)
SecondaryProgression Free Survival (PFS)

PFS by RECIST 1.0 was defined as the duration from date of randomisation to date of progression or death, whichever occurred earlier, based on central independent review.

Time frame:
From randomization until data cut-off (15 July 2014); Up to 1031 days
Reported as:
Median · months
Progression Free Survival (PFS)
monthsPhase II, 200 mg Nintedanib BidPhase II, 400 mg Sorafenib Bid
Progression Free Survival (PFS)5.32 (2.69 to 9.20)3.94 (2.33 to 7.36)
Statistical analysis
  • Phase II, 200 mg Nintedanib Bid vs Phase II, 400 mg Sorafenib Bid · Hazard ratio (hr): 1.351 · 95% CI 0.779 to 2.343Hazard ratio from Cox proportional hazards model stratified by macroscopic vacular invasion, extrahepatic spread, or both present vs both absent. HR below 1 favors Nintedanib.
SecondaryOverall Survival

Overall survival was defined as the duration from date of randomisation to the date of death.

Time frame:
From randomization until data cut-off (15 July 2014); Up to 1031 days
Reported as:
Median · months
Overall Survival
monthsPhase II, 200 mg Nintedanib BidPhase II, 400 mg Sorafenib Bid
Overall Survival11.86 (6.60 to 25.46)11.40 (6.51 to 17.25)
Statistical analysis
  • Phase II, 200 mg Nintedanib Bid vs Phase II, 400 mg Sorafenib Bid · Hazard ratio (hr): 0.877 · 95% CI 0.522 to 1.473Hazard ratio from Cox proportional hazards model stratified by macroscopic vacular invasion, extrahepatic spread, or both present vs both absent. HR below 1 favors Nintedanib.

Adverse events

Collected over From first administration of the trial drug and until 28 days after the last administration of nintedanib or sorafenib, up to 1289 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1 Group 1, 100mg Nintedanib Bid—3/6 (50%)6/6 (100%)
Phase I Group 1, 150mg Nintedanib Bid—1/3 (33.3%)3/3 (100%)
Phase I Group 1, 200mg Nintedanib Bid—4/4 (100%)4/4 (100%)
Phase I Group 2, 50mg Nintedanib Bid—3/3 (100%)3/3 (100%)
Phase I Group 2, 100mg Nintedanib Bid—2/4 (50%)4/4 (100%)
Phase I Group 2, 150mg Nintedanib Bid—3/4 (75%)4/4 (100%)
Phase I Group 2, 200mg Nintedanib Bid—4/8 (50%)7/8 (87.5%)
Phase II, 200 mg Nintedanib Bid—34/62 (54.8%)61/62 (98.4%)
Phase II, 400 mg Sorafenib Bid—14/31 (45.2%)31/31 (100%)
Most frequent serious events
Showing 10 of 77
Most frequent serious events
EventPhase 1 Group 1, 100mg Nintedanib BidPhase I Group 1, 150mg Nintedanib BidPhase I Group 1, 200mg Nintedanib BidPhase I Group 2, 50mg Nintedanib BidPhase I Group 2, 100mg Nintedanib BidPhase I Group 2, 150mg Nintedanib BidPhase I Group 2, 200mg Nintedanib BidPhase II, 200 mg Nintedanib BidPhase II, 400 mg Sorafenib Bid
Abdominal painGastrointestinal disorders0/60/30/42/31/41/40/81/620/31
AscitesGastrointestinal disorders1/60/30/42/30/40/41/81/620/31
NauseaGastrointestinal disorders0/60/30/40/31/42/40/81/620/31
VomitingGastrointestinal disorders0/60/30/41/31/42/41/81/620/31
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/60/30/41/30/42/40/82/623/31
Gastrointestinal haemorrhageGastrointestinal disorders0/61/30/40/30/40/40/81/620/31
Rectal haemorrhageGastrointestinal disorders0/60/30/41/30/40/40/80/620/31
Varices oesophagealGastrointestinal disorders0/60/30/41/30/40/41/81/621/31
PyrexiaGeneral disorders0/60/30/41/30/40/40/80/621/31
Bile duct obstructionHepatobiliary disorders0/61/30/40/30/40/40/80/621/31
Most frequent other events
Showing 10 of 161
Most frequent other events
EventPhase 1 Group 1, 100mg Nintedanib BidPhase I Group 1, 150mg Nintedanib BidPhase I Group 1, 200mg Nintedanib BidPhase I Group 2, 50mg Nintedanib BidPhase I Group 2, 100mg Nintedanib BidPhase I Group 2, 150mg Nintedanib BidPhase I Group 2, 200mg Nintedanib BidPhase II, 200 mg Nintedanib BidPhase II, 400 mg Sorafenib Bid
DiarrhoeaGastrointestinal disorders2/62/33/43/32/43/45/843/6221/31
NauseaGastrointestinal disorders1/63/33/42/31/43/47/829/629/31
VomitingGastrointestinal disorders2/63/33/42/32/41/45/823/629/31
Abdominal distensionGastrointestinal disorders1/60/33/40/31/40/41/81/621/31
FatigueGeneral disorders3/60/33/42/31/42/45/832/6210/31
Influenza like illnessGeneral disorders1/61/33/41/30/41/40/81/620/31
Decreased appetiteMetabolism and nutrition disorders1/60/33/40/32/42/45/823/6213/31
DyspepsiaGastrointestinal disorders1/62/30/40/31/40/41/81/621/31
Aspartate aminotransferase increasedInvestigations0/62/30/40/30/40/42/811/625/31
Blood alkaline phosphatase increasedInvestigations0/62/30/40/31/40/40/86/622/31

Baseline characteristics

Treated set which included all patients who received at least one single dose of trial medication.

Age, Continuous
Age, Continuous(Years)Phase 1 Group 1, 100mg Nintedanib BidPhase I Group 1, 150mg Nintedanib BidPhase I Group 1, 200mg Nintedanib BidPhase I Group 2, 50mg Nintedanib BidPhase I Group 2, 100mg Nintedanib BidPhase I Group 2, 150mg Nintedanib BidPhase I Group 2, 200mg Nintedanib BidPhase II, 200 mg Nintedanib BidPhase II, 400 mg Sorafenib BidTotal
Mean69.7 ± 6.865.0 ± 7.866.5 ± 4.072.3 ± 11.756.3 ± 6.459.3 ± 13.957.0 ± 11.065.4 ± 10.063.1 ± 11.864.2 ± 10.5
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1 Group 1, 100mg Nintedanib BidPhase I Group 1, 150mg Nintedanib BidPhase I Group 1, 200mg Nintedanib BidPhase I Group 2, 50mg Nintedanib BidPhase I Group 2, 100mg Nintedanib BidPhase I Group 2, 150mg Nintedanib BidPhase I Group 2, 200mg Nintedanib BidPhase II, 200 mg Nintedanib BidPhase II, 400 mg Sorafenib BidTotal
Female110001214524
Male52434364826101
08

Study locations

28 sites
  • 1199.37.43001 Boehringer Ingelheim Investigational Site
    Wien, Austria
  • 1199.37.43002 Boehringer Ingelheim Investigational Site
    Wien, Austria
  • 1199.37.33001 Boehringer Ingelheim Investigational Site
    Paris, France
  • 1199.37.33002 Boehringer Ingelheim Investigational Site
    Paris, France
  • 1199.37.49008 Boehringer Ingelheim Investigational Site
    Berlin, Germany
  • 1199.37.49009 Boehringer Ingelheim Investigational Site
    Erlangen, Germany
  • 1199.37.49002 Boehringer Ingelheim Investigational Site
    Freiburg, Germany
  • 1199.37.49001 Boehringer Ingelheim Investigational Site
    Hannover, Germany
  • 1199.37.49010 Boehringer Ingelheim Investigational Site
    Heidelberg, Germany
  • 1199.37.49005 Boehringer Ingelheim Investigational Site
    Jena, Germany
  • 1199.37.49004 Boehringer Ingelheim Investigational Site
    Magdeburg, Germany
  • 1199.37.49003 Boehringer Ingelheim Investigational Site
    München, Germany
  • 1199.37.49006 Boehringer Ingelheim Investigational Site
    Tübingen, Germany
  • 1199.37.36001 Boehringer Ingelheim Investigational Site
    Debrecen, Hungary
  • 1199.37.31002 Boehringer Ingelheim Investigational Site
    Leiden, Netherlands
  • 1199.37.31001 Boehringer Ingelheim Investigational Site
    Utrecht, Netherlands
  • 1199.37.48002 Boehringer Ingelheim Investigational Site
    Olsztyn, Poland
  • 1199.37.48003 Boehringer Ingelheim Investigational Site
    Warsaw, Poland
  • 1199.37.48001 Boehringer Ingelheim Investigational Site
    Warszawa, Poland
  • 1199.37.40002 Boehringer Ingelheim Investigational Site
    Bucharest, Romania
  • 1199.37.40003 Boehringer Ingelheim Investigational Site
    Cluj-Napoca, Romania
  • 1199.37.44001 Boehringer Ingelheim Investigational Site
    Edgbaston, Birmingham, United Kingdom
  • 1199.37.44005 Boehringer Ingelheim Investigational Site
    Glasgow, United Kingdom
  • 1199.37.44008 Boehringer Ingelheim Investigational Site
    Liverpool, United Kingdom
  • 1199.37.44002 Boehringer Ingelheim Investigational Site
    London, United Kingdom
  • 1199.37.44003 Boehringer Ingelheim Investigational Site
    London, United Kingdom
  • 1199.37.44006 Boehringer Ingelheim Investigational Site
    Manchester, United Kingdom
  • 1199.37.44004 Boehringer Ingelheim Investigational Site
    Nottingham, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2009 to primary completion in Jul 2014, 56 months.

Results were first posted in Aug 2015, 1 year after primary completion. A results delay was requested in Aug 2014.

Of 80 industry-sponsored phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 50. This study's 56 months is above that.

Counting every sponsor, half of 429 studies reached it within 43 months; a quarter within 30 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2009
First posted
Oct 29, 2009
StartActual
Oct 22, 2009
Primary completionActual
Jul 14, 2014
CompletionActual
Oct 12, 2016
Results delay requested
Aug 18, 2014
Results first posted
Aug 7, 2015
Last update
Oct 26, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01004003
Responsible party
Sponsor
First posted
Oct 29, 2009
Start date
Oct 22, 2009
Primary completion
Jul 14, 2014
Completion
Oct 12, 2016
Results posted
Aug 7, 2015
Last update
Oct 26, 2017

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nintedanib

Start the discussion